Benefits of Ultra-Early IV tPA Extend to Emergent Large Vessel Occlusions Too (Video)

First study of this question supports prioritizing speed in ELVO cases

For patients with emergent large vessel occlusion (ELVO), ultra-early treatment with intravenous tissue plasminogen activator (IV tPA) increases rates of recanalization and leads to improved clinical outcomes, according to a retrospective study presented at the 2018 International Stroke Conference by Cleveland Clinic researchers.

Advertising Policy

Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services Policy

The study is the first to look at ultra-early thrombolysis — within 60 minutes of symptom onset, the “golden hour” — specifically in the setting of ELVO. It analyzed outcomes among 158 patients who received IV tPA for ELVO strokes at Cleveland Clinic and found statistically significant improvements in rates of recanalization, early neurological improvement and good neurological outcomes at 90 days among those who received IV thrombolysis within 60 minutes relative to those who received it later.

In this three-minute video, senior investigator M. Shazam Hussain, MD, explains what prompted the study and how it may reshape conventional thinking about ELVO therapy.